Announcements Trials
Browse Landscape

Phase

Phase 2 65Phase 3 14Phase 1/2 9Phase NA 5Phase 1 3Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 4Recruiting 3Completed 3Unknown 2Terminated 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

HER2-positive Breast Cancer 1Breast Neoplasms 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Trastuzumab × Clear all
NCT05189067 2022-01-12

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Unknown
190 enrolled
Breast

HER2-positive Breast Cancer

NCT03085368 2017-07-28

A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Peking Union Medical College Hospital

Phase 2/3 Unknown
482 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡